Trial Profile
A Multi-center, Open Label Trial Evaluating the Efficacy , SAfety and the Impact on QUAlity of Life of Infliximab TherapY in Patients With Moderate-to-severe Psoriasis Not Responding to Standard or Biologic Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms ESAQUALITY
- Sponsors Merck Sharp & Dohme
- 10 Oct 2009 New trial record.